List of articles with "Antengene"

Antengene's IND Approval

Antengene's IND Approval

China Shanghai Antengene KEYTRUDA ATG-022
Antengene R&D Insights

Antengene R&D Insights

China Shanghai biotech Clinical Trials Antengene
Antengene ATG-022 Data

Antengene ATG-022 Data

China Shanghai Antengene ATG-022 CLDN18.2
Antengene Unveils ATG-022 Data

Antengene Unveils ATG-022 Data

USA Berlin Antengene ATG-022 CLDN18.2
Antengene at ACR 2025

Antengene at ACR 2025

United States Chicago Antengene ATG-201 CD19xCD3
Antengene's 2025 Results

Antengene's 2025 Results

Shanghai Antengene ATG-022 TCE Platform
Antengene's Financial Results

Antengene's Financial Results

China Shanghai XPOVIO Antengene ATG-022
ATG-022 Breakthrough

ATG-022 Breakthrough

China Shanghai gastric cancer Antengene ATG-022
Antengene's ATG-022 Breakthrough

Antengene's ATG-022 Breakthrough

China Shanghai Antengene ATG-022 Breakthrough Therapy
Antengene at ESMO 2025

Antengene at ESMO 2025

China Shanghai Antengene ATG-022 Claudin 18.2
Antengene Presents Findings

Antengene Presents Findings

United States Chicago Antengene KEYTRUDA ATG-037
Antengene and MSD Team Up

Antengene and MSD Team Up

China Shanghai Antengene KEYTRUDA ATG-022
Antengene at ASCO 2025

Antengene at ASCO 2025

Antengene ASCO 2025 ATG-037
Antengene's 2024 Highlights

Antengene's 2024 Highlights

China Shanghai XPOVIO Clinical Trials Antengene
XPOVIO® Approved in Indonesia

XPOVIO® Approved in Indonesia

XPOVIO Antengene Selinexor
XPOVIO® Approved in Taiwan

XPOVIO® Approved in Taiwan

Taiwan Taipei XPOVIO Multiple Myeloma Antengene
Selinexor Clinical Insights

Selinexor Clinical Insights

China Hong Kong Antengene Selinexor ASH2024

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.